Trial · NCT01186783
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | mean heart rate | 4 days | percenage of patients with a reduction of the mean heart rate of at least 10 bpm 96 hours after the start of trial treatment |
| Secondary | morbidity | 4 days | group-differences and patient-related changes of morbidity measured by serial APACHE II score monitoring and Sequential Organ Failure Assessment (SOFA) score monitoring |
| Secondary | hemodynamic parameters | 4 days | group-differences and patient-related changes of hemodynamic parameters (cardiac index and cardiac power index) as a consequence of ivabradine treatment |
| Secondary | catecholamine dosage | 4 days | required catecholamine dosage measured by a vasopressor score |
| Secondary | microcirculation | 4 days | improvement of microcirculation as measured by sublingual capillary density and flow |
| Secondary | endothelial function | 4 days | improvement of endothelial function as measured by the "Reactive hyperemia peripheral arterial tonometry-index" |
| Secondary | mean heart rate | 48 hours | comparison of the mean heart rate between the treatment and control group after 24 and 48 hours |
| Secondary | mortality | 6 months | 28-day and 6 months mortality |
| Secondary | cardiac autonomic dysfunction | 4 days | impact on cardiac autonomic dysfunction (heart rate variability quantified by time domain measurements (standard deviation of normal to normal interval (SDNN)) and frequency domain measurements (very low frequency (VLF)-, high frequency (HF)- and low frequency (LF)-power) as well as minimum, maximum, day and night heart rate) |
| Secondary | number of participants with adverse events as a measure of safety and tolerability | 6 months | |
| Secondary | plasma levels of ivabradine in patients with MODS | 4 days | daily measurement of plasma levels during the treatment period (4 days) |
| Secondary | Differences of mortality in different age groups and MODS groups | 6 months | age sub-groups: 1. patients \<70 years on day of inclusion 2. patients ≥70 years on day of inclusion MODS sub-groups: 1. patients with cardiogenic MODS 2. patients with septic MODS |
| Secondary | Differences of adverse events in different age groups and MODS groups | 6 months | age sub-groups: 1. patients \<70 years on day of inclusion 2. patients ≥70 years on day of inclusion MODS sub-groups: 1. patients with cardiogenic MODS 2. patients with septic MODS |
| Secondary | Differences of heart rate in different age groups and MODS groups | 6 months | age sub-groups: 1. patients \<70 years on day of inclusion 2. patients ≥70 years on day of inclusion MODS sub-groups: 1. patients with cardiogenic MODS 2. patients with septic MODS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01186783/registered